Your browser doesn't support javascript.
loading
Regional differences in mortality risk and in attenuating or aggravating factors in schizophrenia: A systematic review and meta-analysis.
Solmi, Marco; Croatto, Giovanni; Fornaro, Michele; Schneider, Lynne Kolton; Rohani-Montez, S Christy; Fairley, Leanne; Smith, Nathalie; Bitter, István; Gorwood, Philip; Taipale, Heidi; Tiihonen, Jari; Cortese, Samuele; Dragioti, Elena; Rietz, Ebba Du; Nielsen, Rene Ernst; Firth, Joseph; Fusar-Poli, Paolo; Hartman, Catharina; Holt, Richard I G; Høye, Anne; Koyanagi, Ai; Larsson, Henrik; Lehto, Kelli; Lindgren, Peter; Manchia, Mirko; Nordentoft, Merete; Skonieczna-Zydecka, Karolina; Stubbs, Brendon; Vancampfort, Davy; Boyer, Laurent; De Prisco, Michele; Vieta, Eduard; Correll, Christoph U.
Affiliation
  • Solmi M; SCIENCES lab, Department of Psychiatry, University of Ottawa, Ottawa, ON, Canada; Department of Mental Health, Ottawa Hospital, Ottawa, ON, Canada; Ottawa Hospital Research Institute (OHRI) Clinical Epidemiology Program, University of Ottawa, Ottawa, ON, Canada; School of Epidemiology and Public Hea
  • Croatto G; Mental Health Department, AULSS 3 Serenissima, Mestre, Venice, Italy.
  • Fornaro M; Section of Psychiatry, Department of Neuroscience, Reproductive Science, and Dentistry, Federico II University of Naples, Naples, Italy.
  • Schneider LK; WebMD Global LLC, London, UK.
  • Rohani-Montez SC; WebMD Global LLC, London, UK.
  • Fairley L; WebMD Global LLC, London, UK.
  • Smith N; WebMD Global LLC, London, UK.
  • Bitter I; Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary.
  • Gorwood P; INSERM U1266, Institute of Psychiatry and Neurosciences of Paris (IPNP), Paris, France; GHU Paris Psychiatrie et Neurosciences (CMME, Sainte-Anne Hospital), Université de Paris, Paris, France.
  • Taipale H; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden; Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland; School of Pharmacy, University of Eastern
  • Tiihonen J; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden; Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland.
  • Cortese S; Centre for Innovation in Mental Health, School of Psychology, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, UK; Solent NHS Trust, Southampton, UK; Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampto
  • Dragioti E; Research Laboratory Psychology of Patients, Families, and Health Professionals, Department of Nursing, School of Health Sciences, University of Ioannina, Ioannina, Greece; Pain and Rehabilitation Centre, Department of Medical and Health Sciences, Linköping University, Linköping, Sweden.
  • Rietz ED; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Nielsen RE; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; Department of Psychiatry, Aalborg University Hospital, Aalborg, Denmark.
  • Firth J; Division of Psychology and Mental Health, The University of Manchester, Manchester, United Kingdom.
  • Fusar-Poli P; Early Psychosis: Interventions and Clinical-detection (EPIC) Lab, Department of Psychosis Studies, King's College, London, UK; Department of Brain and Behavioral Sciences, University of Pavia, Italy; Outreach and Support in South-London (OASIS) service, South London and Maudlsey (SLaM) NHS Foundatio
  • Hartman C; University of Groningen, University Medical Center Groningen, Interdisciplinary Centre Psychopathology and Emotion regulation.
  • Holt RIG; Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Høye A; Department of Clinical Medicine, UiT The Arctic University of Norway and Division of Mental Health and Substance Abuse, University Hospital of North Norway, Tromsø, Norway.
  • Koyanagi A; Research and Development Unit, Parc Sanitari Sant Joan de Déu, CIBERSAM, ISCIII, Dr. Antoni Pujadas, 42, Sant Boi de Llobregat, 08830, Barcelona, Spain.
  • Larsson H; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; School of Medical Sciences, Örebro University, Örebro, Sweden.
  • Lehto K; Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia.
  • Lindgren P; Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden; The Swedish Institute for Health Economics, Lund, Sweden.
  • Manchia M; Section of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy; Unit of Clinical Psychiatry, University Hospital Agency of Cagliari, Cagliari, Italy; Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Nordentoft M; Mental Health Centre Copenhagen, Department of Clinical Medicine, Copenhagen University Hospital, Denmark.
  • Skonieczna-Zydecka K; Department of Biochemical Science, Pomeranian Medical University in Szczecin, 71-460 Szczecin, Poland. Electronic address: karzyd@pum.edu.pl.
  • Stubbs B; Physiotherapy Department, South London and Maudsley NHS Foundation Trust, London, UK; Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK.
  • Vancampfort D; Department of Rehabilitation Sciences, KU Leuven, Leuven, Belgium; University Psychiatric Centre KU Leuven, Kortenberg, Leuven, Belgium.
  • Boyer L; AP-HM, Aix-Marseille Univ., CEReSS-Health Service Research and Quality of Life Center, Marseille, France; FondaMental Foundation, Creteil, France.
  • De Prisco M; Bipolar and Depressive Disorders Unit, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.
  • Vieta E; Bipolar and Depressive Disorders Unit, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.
  • Correll CU; Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany; Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA; Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
Eur Neuropsychopharmacol ; 80: 55-69, 2024 Mar.
Article in En | MEDLINE | ID: mdl-38368796
ABSTRACT
People with schizophrenia die prematurely, yet regional differences are unclear. PRISMA 2020-compliant systematic review/random-effects meta-analysis of cohort studies assessing mortality relative risk (RR) versus any control group, and moderators, in people with ICD/DSM-defined schizophrenia, comparing countries and continents. We conducted subgroup, meta-regression analyses, and quality assessment. The primary outcome was all-cause mortality. Secondary outcomes were suicide-, /natural-cause- and other-cause-related mortality. We included 135 studies from Europe (n = 70), North-America (n = 29), Asia (n = 33), Oceania (n = 2), Africa (n = 1). In incident plus prevalent schizophrenia, differences across continents emerged for all-cause mortality (highest in Africa, RR=5.98, 95 %C.I.=4.09-8.74, k = 1, lowest in North-America, RR=2.14, 95 %C.I.=1.92-2.38, k = 16), suicide (highest in Oceania, RR=13.5, 95 %C.I.=10.08-18.07, k = 1, lowest in North-America, RR=4.4, 95 %C.I.=4.07-4.76, k = 6), but not for natural-cause mortality. Europe had the largest association between antipsychotics and lower all-cause mortality/suicide (Asia had the smallest or no significant association, respectively), without differences for natural-cause mortality. Higher country socio-demographic index significantly moderated larger suicide-related and smaller natural-cause-related mortality risk in incident schizophrenia, with reversed associations in prevalent schizophrenia. Antipsychotics had a larger/smaller protective association in incident/prevalent schizophrenia regarding all-cause mortality, and smaller protective association for suicide-related mortality in prevalent schizophrenia. Additional regional differences emerged in incident schizophrenia, across countries, and secondary outcomes. Significant regional differences emerged for all-cause, cause-specific and suicide-related mortality. Natural-cause death was homogeneously increased globally. Moderators differed across countries. Global initiatives are needed to improve physical health in people with schizophrenia, local studies to identify actionable moderators.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Schizophrenia Limits: Humans Country/Region as subject: Africa / Asia / Europa / Oceania Language: En Journal: Eur Neuropsychopharmacol / Eur. neuropsychopharmacol / European neuropsychopharmacology Journal subject: PSICOFARMACOLOGIA Year: 2024 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Schizophrenia Limits: Humans Country/Region as subject: Africa / Asia / Europa / Oceania Language: En Journal: Eur Neuropsychopharmacol / Eur. neuropsychopharmacol / European neuropsychopharmacology Journal subject: PSICOFARMACOLOGIA Year: 2024 Document type: Article Country of publication: